Grail chief growth officer Andrew Partridge sells $1.15m in stock

Chief Growth Officer of GRAIL, Andrew Partridge, divested a block of 7,873 shares on October 5, 2026, through an automatic 'sell-to-cover' transaction. This sale was worth $1,152,528 and executed at a weighted average price of $146.39 per share. The shares were part of the vesting process of awards, intended to satisfy tax obligations. The current stock price of $132.90 is below the transaction price, despite GRAIL's impressive 170% return over the past six months.

Post the sale, Partridge holds 155,865 shares of GRAIL common stock. According to InvestingPro analysis, GRAIL stock may be overvalued, showing high volatility with a beta of 2.84. Investors can access GRAIL's Pro Research Report for more in-depth information.

Recent news surrounding GRAIL includes the FDA advisory committee's unanimous vote to approve the safety and effectiveness of the Galleri multi-cancer early detection test. Canaccord Genuity raised its price target to $150 with a Buy rating, while Mizuho increased its target to $100 with a Neutral rating. RBC Capital has initiated coverage with a Sector Perform rating and a price target of $84, citing challenges related to reimbursement and adoption.

Despite these concerns, the FDA staff showed no significant issues regarding accuracy and safety. These developments suggest a positive outlook for GRAIL's Galleri test pending further regulatory approvals.